ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.
Jefferies Global Healthcare Conference
Presentation Time | Wednesday, June 5 at 9:30 a.m. EST |
Presenters | Raj Kannan, CEO; Louie Naumovski, Interim CMO |
Webcast link | |
Meetings | One-on-one and small group meetings: June 5, 2024 |
Management | Raj Kannan, CEO Joe Skelton, CFO Louie Naumovski, Interim CMO Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.com/
For more information, please contact your Jefferies representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit https://ir.i-mabbiopharma.com/ and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.72 |
| Daily Change: | -0.84 -12.80 |
| Daily Volume: | 4,097,947 |
| Market Cap: | US$659.340M |
October 14, 2025 September 08, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
